flecainide has been researched along with Blood Pressure, Low in 10 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study aimed to report our experience of intravenous flecainide administration in the treatment of paroxysmal atrial fibrillation (PAF) in the Emergency Room (ER)." | 9.12 | [Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the emergency room]. ( Antonelli, D; Darawsha, A; Feldman, A; Freedberg, NA; Rosenfeld, T, 2006) |
| "The efficacy and safety of intravenous flecainide to convert recent-onset atrial fibrillation (AF) (present for greater than or equal to 30 minutes and less than or equal to 72 hours and a ventricular response greater than or equal to 120 beats/min) was investigated." | 9.07 | Efficacy of flecainide for the reversion of acute onset atrial fibrillation. ( Clarke, GM; Coombs, LJ; Dobb, GJ; Donovan, KD; Lee, KY; Murdock, CJ; Weekes, JN, 1992) |
| "Poisoning with flecainide acetate is rare and associated with a high mortality." | 8.80 | [Severe flecainide acetate poisoning. Apropos of a case]. ( Chevrolet, JC; Elamly, A; Maury, P; Metzger, J; Schoenenberger, I; Veragut, B; Vuille, C, 1999) |
| "The study aimed to report our experience of intravenous flecainide administration in the treatment of paroxysmal atrial fibrillation (PAF) in the Emergency Room (ER)." | 5.12 | [Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the emergency room]. ( Antonelli, D; Darawsha, A; Feldman, A; Freedberg, NA; Rosenfeld, T, 2006) |
| "The efficacy and safety of intravenous flecainide to convert recent-onset atrial fibrillation (AF) (present for greater than or equal to 30 minutes and less than or equal to 72 hours and a ventricular response greater than or equal to 120 beats/min) was investigated." | 5.07 | Efficacy of flecainide for the reversion of acute onset atrial fibrillation. ( Clarke, GM; Coombs, LJ; Dobb, GJ; Donovan, KD; Lee, KY; Murdock, CJ; Weekes, JN, 1992) |
| "The relative safety and efficacy of intravenous administration of adenosine, lignocaine, disopyramide, flecainide, and sotalol for termination of stable, induced ventricular tachycardia was assessed in serial trials." | 5.06 | Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia. ( Camm, AJ; Garratt, CJ; Griffith, MJ; Linker, NJ; Ward, DE, 1990) |
| "Poisoning with flecainide acetate is rare and associated with a high mortality." | 4.80 | [Severe flecainide acetate poisoning. Apropos of a case]. ( Chevrolet, JC; Elamly, A; Maury, P; Metzger, J; Schoenenberger, I; Veragut, B; Vuille, C, 1999) |
| "Magnesium sulphate was added to conventional medical therapy in the treatment of persistent severe hypotension and wide QRS complex tachyarrhythmia in an 18-year-old woman presenting with a 1200 mg flecainide overdose." | 3.76 | Management of persistent wide QRS in flecainide overdose with magnesium sulphate. ( Frost, I; Singh, VK; Sinha, A; Williamson, DG, 2010) |
| "Guidelines recommend that initial trial of a "pill-in-the-pocket" (PIP) Class 1C antiarrhythmic drug (AAD) for cardioversion of atrial fibrillation (AF) be performed in a monitored setting because of the potential for adverse reactions." | 1.72 | Safety of Pill-in-the-Pocket Class 1C Antiarrhythmic Drugs for Atrial Fibrillation. ( Arkles, JS; Callans, DJ; Deo, R; Dixit, S; Epstein, AE; Frankel, DS; Guandalini, GS; Hyman, MC; Jarrah, AA; Lin, D; Marchlinski, FE; Markman, TM; Mustin, E; Nazarian, S; Riley, M; Santangeli, P; Schaller, RD; Supple, GE; Tian, Y, 2022) |
| " It is associated with a potent adverse effect profile; however, the effects of flecainide toxicity in the setting of a pacemaker have not been well described." | 1.51 | Flecainide Toxicity Resulting in Pacemaker Latency and Intermittent Failure to Capture. ( Akpunonu, P; Baum, R; Catanzaro, J; Elayi, CS; Rutland, J; Suffredini, JM, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (60.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Markman, TM | 1 |
| Jarrah, AA | 1 |
| Tian, Y | 1 |
| Mustin, E | 1 |
| Guandalini, GS | 1 |
| Lin, D | 1 |
| Epstein, AE | 1 |
| Hyman, MC | 1 |
| Deo, R | 1 |
| Supple, GE | 1 |
| Arkles, JS | 1 |
| Dixit, S | 1 |
| Schaller, RD | 1 |
| Santangeli, P | 1 |
| Nazarian, S | 1 |
| Riley, M | 1 |
| Callans, DJ | 1 |
| Marchlinski, FE | 1 |
| Frankel, DS | 1 |
| Suffredini, JM | 1 |
| Rutland, J | 1 |
| Akpunonu, P | 1 |
| Baum, R | 1 |
| Catanzaro, J | 1 |
| Elayi, CS | 1 |
| Williamson, DG | 1 |
| Sinha, A | 1 |
| Frost, I | 1 |
| Singh, VK | 1 |
| Antonelli, D | 1 |
| Feldman, A | 1 |
| Freedberg, NA | 1 |
| Darawsha, A | 1 |
| Rosenfeld, T | 1 |
| Yasui, RK | 1 |
| Culclasure, TF | 1 |
| Kaufman, D | 1 |
| Freed, CR | 1 |
| Maury, P | 1 |
| Vuille, C | 1 |
| Metzger, J | 1 |
| Veragut, B | 1 |
| Schoenenberger, I | 1 |
| Elamly, A | 1 |
| Chevrolet, JC | 1 |
| Donovan, KD | 2 |
| Dobb, GJ | 2 |
| Coombs, LJ | 2 |
| Lee, KY | 2 |
| Weekes, JN | 2 |
| Murdock, CJ | 2 |
| Clarke, GM | 2 |
| Griffith, MJ | 1 |
| Linker, NJ | 1 |
| Garratt, CJ | 1 |
| Ward, DE | 1 |
| Camm, AJ | 1 |
| Warren, R | 1 |
| Vohra, J | 1 |
| Hunt, D | 1 |
| Hamer, A | 1 |
1 review available for flecainide and Blood Pressure, Low
| Article | Year |
|---|---|
[Severe flecainide acetate poisoning. Apropos of a case].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Biological Availability; Calcium Gluconate | 1999 |
4 trials available for flecainide and Blood Pressure, Low
| Article | Year |
|---|---|
[Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the emergency room].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Emergencies; Female; Flecainide; Humans; Hypotens | 2006 |
Efficacy of flecainide for the reversion of acute onset atrial fibrillation.
Topics: Acute Disease; Arrhythmias, Cardiac; Atrial Fibrillation; Digoxin; Double-Blind Method; Drug Evaluat | 1992 |
Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide.
Topics: Atrial Fibrillation; Coronary Care Units; Digoxin; Double-Blind Method; Drug Therapy, Combination; E | 1991 |
Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia.
Topics: Adenosine; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Clinical Trials as Topic; Disopyramid | 1990 |
5 other studies available for flecainide and Blood Pressure, Low
| Article | Year |
|---|---|
Safety of Pill-in-the-Pocket Class 1C Antiarrhythmic Drugs for Atrial Fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Female; Flecainide; Humans; H | 2022 |
Flecainide Toxicity Resulting in Pacemaker Latency and Intermittent Failure to Capture.
Topics: Acute Kidney Injury; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; El | 2019 |
Management of persistent wide QRS in flecainide overdose with magnesium sulphate.
Topics: Adolescent; Anti-Arrhythmia Agents; Drug Overdose; Electrocardiography; Female; Flecainide; Humans; | 2010 |
Flecainide overdose: is cardiopulmonary support the treatment?
Topics: Adult; Anti-Arrhythmia Agents; Bradycardia; Cardiopulmonary Bypass; Drug Overdose; Fatal Outcome; Fe | 1997 |
Serious interactions of sotalol with amiodarone and flecainide.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Drug Administration Schedule; Drug Interactions; Drug Therap | 1990 |